VIVS Organovo: Forward P/S Multiple

VivoSim Labs Inc (VIVS) management is adapting 3D bioprinting for the preclinical testing of pharma behemoths, maintaining investor confidence. An ethical approach to research minimizes animal usage, supporting ESG principles. Reviewing the projected P/S changes on GURU.Markets, it is evident that the current status is 16.90, confirming the business's reliability due to a broad network of independent laboratories that reduces biotech financial risks.

Organovo - VIVS Market Cap to Expected Sales Ratio (period 04/25/2025 - 11/14/2026)

Metric breakdowns and analytics for VivoSim Labs (VIVS)

- current price and projected stock value:

Stock Price Organovo Holdings, Inc.|VIVS - Average Forecast Price

- company stock capitalization data:

Market Capitalization VivoSim Labs|VIVS - Business Value

- issuer book value statistics:

Book Value per Share Organovo|VIVS - Book Valuation of Business|Market Capitalization to Book Value Ratio organovo.com|VIVS - Cumulative Company Assets

- company total debt and liquidity indicators:

- financial results and valuation multiples details:

VIVS - Annual Net Income|Future Profit VivoSim Labs Inc|VIVS - P/E Multiple|Forward P/E Multiple Organovo Holdings|VIVS - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization VivoSim Labs|VIVS - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months Organovo|VIVS - Net earnings per share for the last 12 months|Quarterly EPS earnings growth organovo.com|VIVS - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year VivoSim Labs Inc

- sales volume and revenue indicators:

VIVS - Company Sales Volume|Company Future Sales Volume VivoSim Labs|VIVS - Market Cap to Sales Volume|Forward Price-to-Revenue Multiple VivoSim Labs

Summary company analytics:Organovo (VIVS)

Patent protection for bio-inks and FDA certification complexities create significant uncertainty regarding the commercialization timelines for VivoSim Labs Inc (VIVS). By analyzing the expected price-to-sales ratio, an investor can view the current share price relative to projected sales, allowing for an assessment of how much future product success the market has currently priced in and whether it is overpaying for potential growth.

Key competitors

Forward P/S Multiple ABT (Abbott)|Thermo Fisher Scientific Inc. (TMO) - Market Cap to Future Revenue Ratio|GE Healthcare Corp - Forward P/S Multiple|MTD (Mettler Toledo Inc) - Market Cap to Projected Revenue|WAT: Forward P/S Multiple|TECH - Market Cap to Expected Sales Ratio|BRKR (Bruker) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Azenta Inc (AZTA)|Forward P/S Multiple VREX|Forward P/S Multiple Semler (SMLR)|Price-to-Projected Revenue Ratio Butterfly Network, Inc. BFLY|mesalabs.com - Price-to-Projected Revenue Ratio|QSI: Forward Price-to-Revenue Multiple|Forward Price to Sales NNOX (Nano-X Imaging)|QTRX: Forward P/S Multiple|Market Cap to Future Revenue Ratio 908 Devices Corporation (MASS)|Price-to-Projected Revenue Ratio CapsoVision, Inc.|MXCT - Projected Price to Revenue|Forward Price-to-Revenue Multiple RPID (Rapid Micro Biosystems)|Forward P/S Multiple Seer Inc (SEER)|Forward P/S Multiple HYPR (Hyperfine Corp)|Market Cap to Expected Sales Ratio FONAR Corporation Inc (FONR)|DXR - Price-to-Projected Revenue Ratio|Future Price to Revenue MDAI|Aclarion, Inc. (ACON) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Akoya Biosciences, Inc.|THMO (ThermoGenesis Holdings Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Talis Biomedical Corp TLIS|Price-to-Projected Revenue Ratio T2 Biosystems, Inc. (TTOO)